Community effectiveness of pyriproxyfen as a dengue vector control method: A systematic review
Pyriproxyfen is highly effective in killing the larvae of dengue transmitting vectors, however the evidence for the reduction of human disease transmission is weak.
The global burden of dengue has risen massively over the past decades. Pyriproxyfen is a slow-acting larvicide with activity against a broad spectrum of public health insect pests and is being used extensively worldwide. Due to its low mammalian toxicity, it is approved by the World Health Organization (WHO) for the treatment of potable water against mosquitoes. A systematic review of the effectiveness of Pyriproxyfen against dengue virus was performed and identified 17 studies. Studies were conducted in Central or South America (7), Southeast Asia (4); USA (2), Martinique (2) and Europe (2). Inconsistent results were observed for efficacy, most probably the result of differences between strains, formulations, and experimental conditions. There was evidence that pyriproxyfen effectively inhibits Aedes adult emergence at concentrations of <1 ppb. Risk of bias was not assessed and studies raged in size from 2 villages (approximately 200 people) to 97,262 people.
Adolescents, Adults, Both sexes (for groups of both male and female persons), Child health, Children, Combatant, Displaced population, Epidemic/Endemic, Health, Healthcare workers, HIV and sexually transmitted infections, Host population, Infections and infectious diseases (all), Internally displaced population, LGBT (lesbian gay bisexual and transgender), Maternal and perinatal health, Minorities, Neonates/infants, Non-combatant, Older people, Persons with disabilities, Pregnant/lactating women, Prisoners/Detainees, Returning population, Sexual and reproductive health, Stateless, Viral fevers/VHF, Zoonotic and other pathogens